Antiphospholipid antibodies in patients with autoimmune blistering disease - 19/08/11

Doi : 10.1016/j.jaad.2006.07.004

Takeshi Echigo, MD, PhD ^a, Minoru Hasegawa, MD, PhD ^a,^⁎ , Makoto Inaoki, MD, PhD ^b, Masahide Yamazaki, MD, PhD ^d, Shinichi Sato, MD, PhD ^c, Kazuhiko Takehara, MD, PhD ^a
^a From the Departments of Dermatology, Kanazawa University Graduate School of Medical Science
^b Kawasaki Medical School, Kurashiki
^c Nagasaki University Graduate School of Biomedical Sciences
^d Department of Internal Medicine (III), Kanazawa University Graduate School of Medical Science

Reprint requests: Minoru Hasegawa, MD, PhD, Department of Dermatology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan.

Kanazawa, Kurashiki, and Nagasaki, Japan

Abstract

Objective

Our purpose was to determine the serum levels and frequency of antiphospholipid antibodies (aPLs) and confirm the clinical importance of these antibodies in patients with autoimmune blistering disease (ABD).

Methods

IgG and IgM anticardiolipin antibodies (aCL), IgG anticardiolipin-β² glycoprotein I complex antibody (aCL/β₂GPI), and IgG antiphosphatidylserine-prothrombin complex antibody (aPS/PT) were examined with an enzyme-linked immunosorbent assay in 71 patients with ABD, including pemphigus vulgaris, pemphigus foliaceus, and bullous pemphigoid.

Results

The prevalence of IgG aCL, IgM aCL, aCL/β₂GPI, and IgG aPS/PT was positive for 22.4%, 9.1%, 9.9%, and 25.4% of the ABD patients, respectively, whereas these antibodies were not detected in any of the normal control subjects. Ten of 20 patients with ABD who were attending our hospital in 2004 tested positive for aPLs, and thromboembolism was detected in 7 of 10 patients with aPLs.